YM raises $15M; La Jolla, Adamis terminate merger agreement;

 @FierceBiotech: Sanofi offers promising survival data on prostate cancer drug cabazitaxel. Article | Follow @FierceBiotech

 @JohnCFierce: Yesterday I calculated that I have written more than two million words on biotech. There has to be a cure.... | Follow @JohnCFierce

> YM BioSciences, announced today that it is raising approximately $15 million in a registered direct offering of units at a price of $1.20 per unit. YM release

> Waltham-based Thermo Fisher Scientific, which has offices in Central Massachusetts, has completed its acquisition of Woburn-based Finnzymes. Finnzymes, which makes tools for scientific experimentation, will join Thermo Fisher's analytical technologies department. According to Thermo Fisher, Finnzymes generated revenues of about $20 million in 2009. Story

> La Jolla Pharmaceutical  and Adamis Pharmaceuticals Corporation have agreed to terminate their merger agreement relating to the proposed merger of the two companies. La Jolla release

> Anthera Pharmaceuticals, a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of 6 million shares of common stock at a price of $7.00 per share. Anthera release

And Finally... The Wall Street Journal gets a tour of J. Craig Venter's his new home in La Jolla, CA. Article

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.